Business Description
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Business History
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -22.40
Total Equity: $3.83M
Shares: 958,443
Total Debt: $0.00
Cash: $3.09M
EBITDA: -$21.40M
Total Debt: $0.00
Cash: $3.09M
Revenue: $2.49M
Shares: 958,443
Revenue: $2.49M
Revenue: $2.49M
Revenue: $2.49M
Total Equity: $3.83M
Tax Rate: 0.0%
Equity: $3.83M
Total Debt: $0.00
Cash: $3.09M
Current Liabilities: $1.94M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $3.83M
Shares: 958,443
Shares: 958,443
CapEx: -$27,612
Shares: 958,443
Stock Price: $1.33
Net Income: -$21.46M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 23, 2026 7:53am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $385,501 | $81,526 | $0 | $4.0M | $2.5M |
| Cost of Revenue | $0 | $9.1M | $20.7M | $95,368 | $0 |
| Gross Profit | $385,501 | -$9.0M | -$20.7M | $3.9M | $2.5M |
| Operating Expenses | $19.1M | $5.0M | $6.0M | $29.0M | $24.1M |
| Operating Income | -$18.7M | -$14.0M | -$26.7M | -$25.1M | -$21.6M |
| Net Income | -$18.6M | -$14.0M | -$26.0M | -$25.0M | -$21.5M |
| EBITDA | -$18.5M | -$14.0M | -$25.9M | -$24.9M | -$21.4M |
| EPS | $-182.50 | $-138.00 | $-255.50 | $-120.50 | $-22.40 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 23, 2026 7:53am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $11.4M | $27.6M | $6.5M | $5.5M | $3.1M |
| Total Current Assets | $11.6M | $28.9M | $7.9M | $7.9M | $5.3M |
| Total Assets | $11.8M | $31.3M | $9.3M | $8.2M | $6.3M |
| Current Liabilities | $5.4M | $4.7M | $3.5M | $3.1M | $1.9M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.4M | $4.7M | $3.5M | $3.1M | $2.5M |
| Total Equity | $4.4M | $26.6M | $5.8M | $5.0M | $3.8M |
| Retained Earnings | -$64.4M | -$78.4M | -$104.4M | -$129.4M | -$150.8M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 7:53am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.2M | -$19.0M | -$25.2M | -$24.7M | -$21.5M |
| Capital Expenditure | $-47,718 | $-134,258 | $-48,946 | $-20,653 | $-27,612 |
| Free Cash Flow | -$11.2M | -$19.2M | -$25.2M | -$24.7M | -$21.5M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-1,000 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.5M | $16.2M | -$21.2M | $-945,648 | -$2.4M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 2:26pm (18h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$519.6M $519.6M – $519.6M
|
$224.8M $224.8M – $224.8M
|
$112.4M $112.4M – $112.4M
|
$196.7M $196.7M – $196.7M
|
| EBITDA |
-$311.7M -$311.7M – -$311.7M
|
-$134.9M -$134.9M – -$134.9M
|
-$67.5M -$67.5M – -$67.5M
|
-$118.0M -$118.0M – -$118.0M
|
| Net Income |
-$2.9M -$2.9M – -$2.9M
|
-$2.8M -$2.8M – -$2.8M
|
$4.1M $4.1M – $4.1M
|
$7.0M $7.0M – $7.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 23, 2026 7:53am (4d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -78.9% | -100.0% | — | -37.1% |
| Gross Profit Growth | -2,445.5% | -129.2% | +118.6% | -35.5% |
| Operating Income Growth | +25.2% | -90.6% | +6.0% | +13.9% |
| Net Income Growth | +24.5% | -85.2% | +3.8% | +14.1% |
| EBITDA Growth | +24.6% | -85.4% | +3.9% | +14.0% |
Narrative Economics
market-narrative step).